DC
Decheng Capital Portfolio holdings
AUM
$396M
This Quarter Return
+11.95%
1 Year Return
-5.21%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$422M
AUM Growth
+$422M
(+29%)
Cap. Flow
+$59.1M
Cap. Flow
% of AUM
14%
Top 10 Holdings %
Top 10 Hldgs %
87.52%
Holding
26
New
2
Increased
10
Reduced
2
Closed
–
Top Buys
| 1 |
Nuvation Bio
NUVB
|
$43.5M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
$7.23M |
| 3 |
NewAmsterdam Pharma
NAMS
|
$3.15M |
| 4 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$1.88M |
| 5 |
Arcellx
ACLX
|
$1.67M |
Top Sells
| 1 |
Illumina
ILMN
|
$1.83M |
| 2 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$116K |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.04B
| $207M | 48.96% | 5,478,810 +20,000 | +0.4% | +$755K |
|
|
2
Nuvation Bio
NUVB
$1.02B
| $59.4M | 14.08% | 25,954,439 +19,004,200 | +273% | +$43.5M |
|
|
3
Phathom Pharmaceuticals
PHAT
$864M
| $22.6M | 5.35% | 1,250,000 +400,000 | +47% | +$7.23M |
|
4
Arcus Biosciences
RCUS
$1.13B
| $13.3M | 3.15% | 869,790 | – | – |
|
5
Krystal Biotech
KRYS
$4.27B
| $13.1M | 3.09% | 71,772 +6,000 | +9% | +$1.09M |
|
|
6
Illumina
ILMN
$15.8B
| $12.4M | 2.93% | 94,767 -14,000 | -13% | -$1.83M |
|
7
Zentalis Pharmaceuticals
ZNTL
$122M
| $11.4M | 2.71% | 3,108,095 +37,653 | +1% | +$139K |
|
8
BeyondSpring
BYSI
$69.4M
| $11.4M | 2.69% | 4,958,143 | – | – |
|
|
9
NewAmsterdam Pharma
NAMS
$2.71B
| $9.79M | 2.32% | 590,000 +190,000 | +48% | +$3.15M |
|
10
Merus
MRUS
$4.98B
| $9.45M | 2.24% | 189,098 +10,000 | +6% | +$500K |
|
11
MoonLake Immunotherapeutics
MLTX
$3.54B
| $8.4M | 1.99% | 166,600 | – | – |
|
12
Crinetics Pharmaceuticals
CRNX
$2.92B
| $8.07M | 1.91% | 157,958 | – | – |
|
13
Legend Biotech
LEGN
$6.41B
| $5.29M | 1.25% | 108,558 +10,000 | +10% | +$487K |
|
14
Cytokinetics
CYTK
$4.23B
| $4.97M | 1.18% | 94,043 | – | – |
|
15
Aura Biosciences
AURA
$389M
| $4.59M | 1.09% | 515,555 | – | – |
|
16
GeneDx Holdings
WGS
$3.72B
| $4.4M | 1.04% | 103,604 | – | – |
|
17
4D Molecular Therapeutics
FDMT
$288M
| $4.3M | 1.02% | 397,835 +50,000 | +14% | +$541K |
|
18
Equillium
EQ
$62.2M
| $3.7M | 0.88% | 4,447,308 | – | – |
|
19
Vera Therapeutics
VERA
$1.38B
| $3.08M | 0.73% | 69,767 | – | – |
|
|
LBPH
20
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.88M | 0.44% | +56,350 | New | +$1.88M |
|
|
21
Arcellx
ACLX
$3.85B
| $1.77M | 0.42% | 21,177 +20,000 | +1,699% | +$1.67M |
|
22
Pyxis Oncology
PYXS
$79.4M
| $1.2M | 0.28% | 326,810 | – | – |
|
23
AtriCure
ATRC
$1.84B
| $751K | 0.18% | 26,797 | – | – |
|
|
GRAL
24
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $133K | 0.03% | 9,684 -8,443 | -47% | -$116K |
|
25
Revolution Medicines
RVMD
$7.1B
| $90.7K | 0.02% | +2,000 | New | +$90.7K |
|